Ampullary cancer - a separate clinical entity?

Histopathology

Volumn 64, Issue 6, 2014, Pages 759-768

  Perysinakis, Iraklis ^a   Margaris, Ilias ^a   Kouraklis, Gregory ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Ampullary cancer; Differentiation; Immunohistochemical markers; Intestinal; Pancreatobiliary

Indexed keywords

CANCER PROGNOSIS; CANCER STAGING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; PATHOGENESIS; PERINEURAL INVASION; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; TUMOR DIFFERENTIATION; VATER PAPILLA CARCINOMA; ADENOCARCINOMA; BILE DUCT TUMOR; PATHOLOGY; PROGNOSIS; VATER PAPILLA;

TUMOR MARKER;

ADENOCARCINOMA; AMPULLA OF VATER; COMMON BILE DUCT NEOPLASMS; HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898059256     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12324     Document Type: Review

References (65)

1. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am. J. Surg. Pathol. 2005; 29; 359-367.
2. Santini D, Tonini G, Vecchio FM et al. Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma. J. Clin. Pathol. 2005; 58; 159-165.
3. Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5625 cases from the SEER program. J. Surg. Oncol. 2009; 100; 598-605.
4. Goodman MT, Yamamoto J. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. Cancer Causes Control 2007; 18; 415-422.
5. Heinrich S, Clavien PA. Ampullary cancer. Curr. Opin. Gastroenterol. 2010; 26; 280-285.
6. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumours. Chichester, West Sussex;/Hoboken, NJ: Wiley-Blackwell, 2010.
7. Duffy JP, Hines OJ, Liu JH et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch. Surg. 2003; 138; 941-948; discussion 8-50.
8. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann. Surg. 2002; 236; 355-366; discussion 66-68.
9. de Castro SM, van Heek NT, Kuhlmann KF et al. Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery 2004; 136; 994-1002.
10. Todoroki T, Koike N, Morishita Y et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann. Surg. Oncol. 2003; 10; 1176-1183.
11. Jean M, Dua K. Tumours of the ampulla of Vater. Curr. Gastroenterol. Rep. 2003; 5; 171-175.
12. Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J. Hepatobiliary Pancreat. Surg. 2004; 11; 301-309.
13. Tuncer E, Turk NS, Arici S, Duzcan SE, Demirkan NC. Expression of p16 protein and cyclin D1 in periampullary carcinomas. Turk Patoloji Derg. 2011; 27; 17-22.
14. Lowe MC, Coban I, Adsay NV et al. Important prognostic factors in adenocarcinoma of the ampulla of Vater. Am. Surg. 2009; 75; 754-760; discussion 61.
15. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF. Factors predictive of survival in ampullary carcinoma. Ann. Surg. 1998; 228; 87-94.
16. Schirmacher P, Buchler MW. Ampullary adenocarcinoma - differentiation matters. BMC Cancer 2008; 8; 251.
17. Kawabata Y, Tanaka T, Nishisaka T, Inao T, Nishi T, Yano S. Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: correlation with tumour progression and prognosis. Diagn. Pathol. 2010; 5; 75.
18. Frierson HF Jr. The gross anatomy and histology of the gallbladder, extrahepatic bile ducts, Vaterian system, and minor papilla. Am. J. Surg. Pathol. 1989; 13; 146-162.
19. Kimura W, Futakawa N, Yamagata S et al. Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Jpn. J. Cancer Res. 1994; 85; 161-166.
20. Albores-Saavedra J, Henson DE, Klimstra DS, Armed Forces Institute of Pathology, Universities Associated for Research, Education in Pathology I. Tumours of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Washington, DC: Armed Forces Institute of Pathology, 2000 (available from the American Registry of Pathology, Washington, DC, USA).
21. Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J. Surg. Oncol. 2011; 105; 266-272.
22. Kim WS, Choi DW, Choi SH, Heo JS, You DD, Lee HG. Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J. Surg. Oncol. 2012; 105; 266-272.
23. Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am. J. Surg. Pathol. 2004; 28; 875-882.
24. Ruemmele P, Dietmaier W, Terracciano L et al. Histopathologic features and microsatellite instability of cancers of the papilla of Vater and their precursor lesions. Am. J. Surg. Pathol. 2009; 33; 691-704.
25. Westgaard A, Schjolberg AR, Cvancarova M, Eide TJ, Clausen OP, Gladhaug IP. Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours. Histopathology 2009; 54; 337-347.
26. Westgaard A, Tafjord S, Farstad IN et al. Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 2008; 8; 170.
27. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Tumours of the ampulla of Vater: histopathologic classification and predictors of survival. J. Am. Coll. Surg. 2008; 207; 210-218.
28. Roh YH, Kim YH, Lee HW et al. The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology 2007; 54; 1641-1644.
29. Albores-Saavedra J, Simpson K, Dancer YJ, Hruban R. Intestinal type adenocarcinoma: a previously unrecognized histologic variant of ductal carcinoma of the pancreas. Ann. Diagn. Pathol. 2007; 11; 3-9.
30. Matsumoto K, Mizoshita T, Tsukamoto T et al. Cdx2 expression in pancreatic tumours: relationship with prognosis of invasive ductal carcinomas. Oncol. Rep. 2004; 12; 1239-1243.
31. Hansel DE, Maitra A, Lin JW et al. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater. J. Clin. Oncol. 2005; 23; 1811-1818.
32. Matsubayashi H, Watanabe H, Yamaguchi T et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumours of the papilla of Vater. Cancer 1999; 86; 596-607.
33. Sessa F, Furlan D, Zampatti C, Carnevali I, Franzi F, Capella C. Prognostic factors for ampullary adenocarcinomas: tumour stage, tumour histology, tumour location, immunohistochemistry and microsatellite instability. Virchows Arch. 2007; 451; 649-657.
34. Fischer HP, Zhou H. [Pathogenesis and histomorphology of ampullary carcinomas and their precursor lesions. Review and individual findings]. Pathologe 2003; 24; 196-203.
35. Morini S, Perrone G, Borzomati D et al. Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival. Pancreas 2012; 42; 60-66.
36. Takashima M, Ueki T, Nagai E et al. Carcinoma of the ampulla of Vater associated with or without adenoma: a clinicopathologic analysis of 198 cases with reference to p53 and Ki-67 immunohistochemical expressions. Mod. Pathol. 2000; 13; 1300-1307.
37. Park S, Kim SW, Lee BL, Jung EJ, Kim WH. Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. Hepatogastroenterology 2006; 53; 28-32.
38. Liu TH, Chen J, Zeng XJ. Histogenesis of pancreatic head and ampullary region carcinoma. Chin. Med. J. (Engl.) 1983; 96; 167-174.
39. Agoff SN, Crispin DA, Bronner MP, Dail DH, Hawes SE, Haggitt RC. Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod. Pathol. 2001; 14; 139-146.
40. Kimura W, Futakawa N, Zhao B. Neoplastic diseases of the papilla of Vater. J. Hepatobiliary Pancreat. Surg. 2004; 11; 223-231.
41. Younes M, Riley S, Genta RM, Mosharaf M, Mody DR. p53 protein accumulation in tumours of the ampulla of Vater. Cancer 1995; 76; 1150-1154.
42. Hsu HP, Shan YS, Jin YT, Lai MD, Lin PW. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J. Surg. Oncol. 2010; 101; 356-362.
43. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch. Surg. 2001; 386; 163-171.
44. Scarpa A, Di Pace C, Talamini G et al. Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. Gut 2000; 46; 842-848.
45. Lee JH, Lee KG, Ryou H et al. Significance analysis of histologic type and perineural invasion as prognostic factors after curative resection of ampulla of Vater carcinoma. Hepatogastroenterology 2010; 57; 646-652.
46. Qiao QL, Zhao YG, Ye ML et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J. Surg. 2007; 31; 137-143; discussion 44-46.
47. Yokoyama N, Shirai Y, Wakai T, Nagakura S, Akazawa K, Hatakeyama K. Jaundice at presentation heralds advanced disease and poor prognosis in patients with ampullary carcinoma. World J. Surg. 2005; 29; 519-523.
48. Adsay V, Ohike N, Tajiri T et al. Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am. J. Surg. Pathol. 2012; 36; 1592-1608.
49. Ajiki T, Kamigaki T, Hasegawa Y et al. Proliferating cell nuclear antigen, p53, and c-erbB-2 expression in relation to clinicopathological variables and prognosis in cancer of the ampulla of Vater. Hepatogastroenterology 2001; 48; 1266-1270.
50. Isozaki H, Okajima K, Ichinona T et al. The significance of proliferating cell nuclear antigen (PCNA) expression in cancer of the ampulla of Vater in terms of prognosis. Surg. Today 1994; 24; 494-499.
51. Crucitti A, Masetti R, Breccia C et al. Ampullary carcinoma: prognostic significance of ploidy, cell-cycle analysis and proliferating cell nuclear antigen (PCNA). Hepatogastroenterology 1999; 46; 1187-1191.
52. Achille A, Biasi MO, Zamboni G et al. Cancers of the papilla of Vater: mutator phenotype is associated with good prognosis. Clin. Cancer Res. 1997; 3; 1841-1847.
53. Suto T, Habano W, Sugai T et al. Infrequent microsatellite instability in biliary tract cancer. J. Surg. Oncol. 2001; 76; 121-126.
54. Imai Y, Tsurutani N, Oda H, Inoue T, Ishikawa T. Genetic instability and mutation of the TGF-beta-receptor-II gene in ampullary carcinomas. Int. J. Cancer 1998; 76; 407-411.
55. Chang DK, Jamieson NB, Johns AL et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater. J. Clin. Oncol. 2013; 31; 1348-1356.
56. Park SH, Kim YI, Park YH et al. Clinicopathologic correlation of p53 protein overexpression in adenoma and carcinoma of the ampulla of Vater. World J. Surg. 2000; 24; 54-59.
57. Zhu L, Kim K, Domenico DR, Appert HE, Howard JM. Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. J. Surg. Oncol. 1996; 61; 100-105.
58. Yamazaki K, Hanami K, Nagao T, Asoh A, Sugano I, Ishida Y. Increased cyclin D1 expression in cancer of the ampulla of Vater: relevance to nuclear beta catenin accumulation and k-ras gene mutation. Mol. Pathol. 2003; 56; 336-341.
59. Chang MC, Chang YT, Sun CT, Chiu YF, Lin JT, Tien YW. Differential expressions of cyclin D1 associated with better prognosis of cancers of ampulla of Vater. World J. Surg. 2007; 31; 1135-1141.
60. Giannopoulos G, Pavlakis K, Parasi A et al. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008; 28; 1875-1881.
61. Bramhall SR, Stamp GW, Dunn J, Lemoine NR, Neoptolemos JP. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br. J. Cancer 1996; 73; 972-978.
62. Hsu HP, Yang TM, Hsieh YH, Shan YS, Lin PW. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann. Surg. Oncol. 2007; 14; 50-60.
63. Storr SJ, Zaitoun AM, Arora A et al. Calpain system protein expression in carcinomas of the pancreas, bile duct and ampulla. BMC Cancer 2012; 12; 511.
64. Lee CS, Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol. Res. Pract. 1995; 191; 1087-1091.
65. Friess H, Wang L, Zhu Z et al. Growth factor receptors are differentially expressed in cancers of the papilla of Vater and pancreas. Ann. Surg. 1999; 230; 767-774; discussion 74-75.